MVM Medizinische Verwaltungs und Managementgesellschaft mbH

The Studienzentrum UnterEms at MVM Medizinische Verwaltungs und Managementgesellschaft mbH is conducting a series of studies focused on colorectal cancer and rectal cancer. These trials aim to improve outcomes such as disease‑free survival, organ preservation, and the effectiveness of adjuvant or peri‑operative therapies for patients across stages II to metastatic disease.

• Evaluating adjuvant chemotherapy guided by ctDNA status after resection of stage II colon cancer
• Comparing active post‑resection chemotherapy with structured follow‑up in metastatic colorectal disease
• Testing organ preservation approaches in intermediate‑ and high‑risk rectal cancer using short‑course radiotherapy or chemoradiotherapy
• Investigating peri‑operative immunotherapy for MSI‑high or MMR‑deficient colorectal tumors unsuitable for oxaliplatin

Together, these investigations reflect the site’s commitment to advancing therapeutic strategies for digestive system malignancies and to offering patients access to innovative treatment options.

Research at the center also encompasses HR+/HER2‑negative early breast cancer, targeting improved invasive disease‑free survival through personalized adjuvant regimens that combine endocrine therapy with a CDK4/6 inhibitor.

• Comparing CDK4/6 inhibitor plus endocrine therapy versus standard endocrine therapy in intermediate to high‑risk early breast cancer
• Utilizing dynamic molecular markers to adjust adjuvant treatment intensity
• Assessing long‑term survival benefits of combined targeted and hormonal therapy

These neoplasm‑focused trials underline the site’s dedication to delivering cutting‑edge cancer care and expanding therapeutic options for patients with breast malignancies.